Bimekizumab Impact on Patient-Reported Outcomes in Plaque Psoriasis: 4-Year Results from BE SURE, BE VIVID, BE READY, and BE BRIGHT

By afschroeder • December 9, 2025

Armstrong A, Papp KA, Lebwohl M, Savage LJ, Yamanaka K, Vlase DE, Warham R, Lambert J, López Pinto JM, Wixted K, Thaçi D. Bimekizumab Impact on Patient-Reported Outcomes in Plaque Psoriasis: 4-Year Results from BE SURE, BE VIVID, BE READY, and BE BRIGHT. Dermatol Ther (Heidelb). 2025 Dec 8. doi: 10.1007/s13555-025-01595-9. Epub ahead of print. PMID: 41359217.

Tags: bimekizumab, biologic therapy, Dermatology, health-related quality of life, IL-17A/F, long-term treatment, patient-reported outcomes, Phase 3 clinical trials, plaque psoriasis, Publications

US expert opinions on the treatment of bullous pemphigoid based on guidelines from the European Academy of Dermatology and Venereology

Kasperkiewicz M, Thapa M, Adotama P, Tomayko MM, Culton DA. US expert opinions on the treatment of bullous pemphigoid based on guidelines from the European[...]

Single-cell and spatial profiling reveal cDC2A-CXCL13+CD8+ T-epithelial cell crosstalk and cytotoxicity through TNFRSF9 in cutaneous and mucosal lichen planus

Jiang R, Bogle R, Xing X, Kirma J, Fox J, Harms PW, Do T, Billi AC, Kahlenberg JM, Modlin RL, Teles R, West J, Mangold[...]

Concordance Between Patient- and Physician-Reported Improvement With Dupilumab in Atopic Dermatitis

Conde G, Carmenate Y, Bello G, Armstrong AW. Concordance Between Patient- and Physician-Reported Improvement With Dupilumab in Atopic Dermatitis. J Dermatol. 2026 Mar 13. doi:[...]